Sulfadiazine – 50 g

Brand:
Cayman
CAS:
68-35-9
Storage:
4
UN-No:
Non-Hazardous - /

Sulfadiazine is a sulfonamide antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria.{38582,36439,36440,36441} It inhibits dihydropteroate synthase (DHPS), which converts a pteridine and 4-aminobenzoic acid (PABA; Item No. 18659) to dihydropteroate, an intermediate in folate biosynthesis.{38582} Sulfadiazine inhibits recombinant P. carinii DHPS (IC50 = 0.19 μM). It inhibits the growth of clinical isolates of M. tuberculosis (MIC90 = 10 mg/L) and of N. meningitidis (MICs = 5-2,000 mg/L).{36439,36440} Sulfadiazine also inhibits the growth of A. pleuropneumoniae, S. choleraesuis, S. typhimurium, P. multocida, S. equi, and S. suis (MIC90 = 16473).{36441} In vivo, sulfadiazine (40 mg/kg per day) results in a 36% 90-day survival in a mouse model of lethal T. gondii infection when used in combination with pyrimethamine (Item No. 16472).{36442} Formulations containing sulfadiazine have been used to treat rheumatic fever and various infections, and, in a dual treatment with pyrimethamine, to treat toxoplasmosis.  

 

Available on backorder

SKU: 23719 - 50 g Category:

Description

A sulfonamide antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria; inhibits recombinant P. carinii DHPS (IC50 = 0.19 μM); inhibits the growth of clinical isolates of M. tuberculosis (MIC90 = 10 mg/L) and of N. meningitidis (MICs = 5-2,000 mg/L); inhibits the growth of A. pleuropneumoniae, S. choleraesuis, S. typhimurium, P. multocida, S. equi, and S. suis (MIC90s = T. gondii infection when used at a dose of 40 mg/kg per day in combination with pyrimethamine


Formal name: 4-amino-N-2-pyrimidinyl-benzenesulfonamide

Synonyms:  NSC 35600

Molecular weight: 250.3

CAS: 68-35-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antibiotics|Sulfonamides||Product Type|Biochemicals|Antiparasitics|Antiprotozoals||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|Tuberculosis||Research Area|Infectious Disease|Parasitic Diseases|Toxoplasmosis